TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04387552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Safe Sleep Mobile Health (mHealth) Messaging
Description: Participants will receive prenatal Safe Sleep mHealth messaging starting at 34 weeks gestation until birth of their baby.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Safe Sleep Mobile Health (mHealth) Messaging
Description: Participants will receive prenatal Safe Sleep mHealth messaging starting at 34 weeks gestation until birth of their baby.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Breastfeeding Mobile Health (mHealth) Messaging
Description: Participants will receive prenatal Breastfeeding mHealth messaging starting at 34 weeks gestation until birth of their baby.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Breastfeeding Mobile Health (mHealth) Messaging
Description: Participants will receive prenatal Breastfeeding mHealth messaging starting at 34 weeks gestation until birth of their baby.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal Safe Sleep Mobile Health (mHealth) Messaging
Description: Upon birth of baby, participants will begin receiving postnatal Safe Sleep mHealth messaging for a two month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal Safe Sleep Mobile Health (mHealth) Messaging
Description: Upon birth of baby, participants will begin receiving postnatal Safe Sleep mHealth messaging for a two month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal Breastfeeding Mobile Health (mHealth) Messaging
Description: Upon birth of baby, participants will begin receiving postnatal Breastfeeding mHealth messaging for a two month period.
Study: NCT06649266

Intervention type: DRUG
Group type: OTHER
Intervention: RBD1016
Description: RBD1016, active drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo that is identical in appearance and volume to the doses of active IMP.
Study: NCT06585696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CU-20101 treatment for Moderate to Severe Glabellar Striae
Description: Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20101 treatment for Moderate to Severe Glabellar Striae
Description: Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36).
Study: NCT05683132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed CBT-I
Description: 5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Psychoeducation
Description: 5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
Study: NCT05121337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian-Assisted DASH groceries
Description: The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed shopping
Description: Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend.
Study: NCT06380179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THOR3 training + Photobiomodulation Therapy (PBMT)
Description: PBMT will be delivered at 32-40W (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.~PBMT will be delivered by a trained study team member using the LightForce® XLi 40W device with the Smart Hand Piece technology, which has a built-in accelerometer in the hand piece that controls the speed of light delivery to the treatment area. The trained team members will use the Smart Hand Piece technology, which assesses the operator's speed and provides real-time visual and sensory feedback calibrated to shut-off when moving too slowly and warns the operator when moving too quickly by vibrating. Treatment is delivered through a flexible optical fiber threaded through the hand piece, which contains a rolling glass massage ball.
Study: NCT06738043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Infusion (Placebo)
Description: A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
Study: NCT06380179

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: THOR3 training + sham PBMT
Description: Sham PBMT will be provided by a trained study team member. Sham PBMT will be delivered in the same manner as indicated for the PBMT process above, but the device will stay in standby mode (i.e., the treatment mode will not be turned on). As infrared light is invisible to the naked eye, the only visible difference between treatment and standby modes is the presence of a few tiny amber lights (these lights are on during treatment mode).
Study: NCT06654271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic assisted bronchoscopy (RAB)
Description: Participants allocated to the robotic assisted bronchoscopy arm will undergo robotic assisted bronchoscopy with integrated cone beam computed tomography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic navigation bronchoscopy (ENB)
Description: Participants allocated to the electromagnetic navigation bronchoscopy arm will undergo electromagnetic navigation bronchoscopy with integrated digital tomosynthesis
Study: NCT06655675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the umbilical artery
Study: NCT06738836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-EDG-7500
Description: Oral liquid suspension
Study: NCT06738888

Intervention type: OTHER
Intervention: Observations on clinicopathological factors influencing the difficulty of surgery
Description: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD

Intervention type: OTHER
Intervention: Observations on clinicopathological factors influencing the difficulty of surgery
Description: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD
Study: NCT05668858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study: NCT06740422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuanhuang Runtong Tablet
Description: A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xuanhuang Runtong Tablet Simulator
Description: Xuanhuang Runtong Tablet Simulator
Study: NCT06168851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 antibody Injection
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study: NCT06387199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide with 4 meal strategies
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo with 4 meal strategies
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
Study: NCT04982913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Study: NCT05290597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI363
Description: a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
Study: NCT05921630

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Patient education before pulmonary function test
Study: NCT04982913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Study: NCT04978753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;
Study: NCT05460780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MATTISSE TEC
Description: Tissue engineering chamber MATTISSE
Study: NCT04387552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal Breastfeeding Mobile Health (mHealth) Messaging
Description: Upon birth of baby, participants will begin receiving postnatal Breastfeeding mHealth messaging for a two month period.
Study: NCT05486156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A Time with e-Nature
Description: Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Time with e-Nature
Description: Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group.
Study: NCT06532565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2121
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2121
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2121
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2121
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously
Study: NCT05201339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard method
Description: Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hean and Neck Rotation
Description: After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
Study: NCT05501886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpelisib
Description: Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
Study: NCT05574270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IC-8 Intraocular Lens (IOL)
Description: A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
Study: NCT05885412

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RP-A601
Description: RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
Study: NCT06541145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Participants will place a pea-sized amount (or approximately 1cm ribbon) of 2% mupirocin ointment (Duke formulary) on a cotton swab and gently massage it into the anterior nares twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine baths
Description: Participants will be instructed to use pre-packaged chlorhexidine cloths. Each cloth will be used to wipe designated body areas (i.e., arms, legs, chest and neck, back and perineum) once a day for 5 days. These are inexpensive cloths that are easy to use and have been shown to be effective at eradicating Staph aureus carriage. Ideally, participants will be instructed not to rinse off immediately after using the cloths. Baths should be performed on the same 5 days as they apply the intranasal mupirocin.
Study: NCT05183126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time.
Study: NCT05387954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Description: PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulant, Direct-Acting
Description: Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet therapy
Description: Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Description: Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
Study: NCT04823169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: podobarometry
Description: podobarometric measures on day 7 and day 30
Study: NCT06541327

Intervention type: DRUG
Intervention: Chimeric Antigen Receptor
Description: CAR-T
Study: NCT04931810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Nations Breath of Life
Description: Same.